Transcriptomics

Dataset Information

0

Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 platform trial 


ABSTRACT: Durvalumab with olaparib was one of the experimental regimens evaluated in I-SPY 2, a neoadjuvant platform trial for high risk, early stage breast cancer, and graduated in the HER2- and HR+HER2- signatures. We hypothesized that (pre-treatment) expression-based immune signatures may predict response to the immune checkpoint inhibitor durvalumab and signatures related to DNA repair deficiency (DRD) may associate with response to olaparib. In this analysis, we assessed 13 expression based signatures related to immune, DRD, proliferation and estrogen signaling as specific predictor of pathologic complete response (pCR) to durvalumab/olaparib. 

ORGANISM(S): Homo sapiens

PROVIDER: GSE173839 | GEO | 2021/06/10

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2021-08-24 | GSE181574 | GEO
| PRJNA727320 | ENA
2020-09-20 | GSE149322 | GEO
2021-08-24 | GSE180962 | GEO
2022-05-25 | GSE196096 | GEO
2020-09-20 | GSE150575 | GEO
2024-07-11 | GSE271668 | GEO
2020-10-15 | GSE139050 | GEO
2023-11-26 | GSE248378 | GEO
2020-07-26 | GSE147537 | GEO